Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration
February 28 2025 - 6:00AM
Achilles Therapeutics plc (NASDAQ: ACHL) (the Company) today
announced that it has formally notified The Nasdaq Stock Market LLC
(Nasdaq) of its intention to voluntarily delist its American
Depositary Shares (ADSs) from Nasdaq and its intent to deregister
its ADSs from the Securities and Exchange Commission (SEC) under
Section 12(b) of the Securities Exchange Act of 1934 (Exchange
Act). As previously reported, the Company has called a General
Meeting for March 20, 2025 to obtain shareholder approval to
commence a members’ voluntary liquidation. The planned delisting of
the ADSs is being undertaken in connection with the contemplated
liquidation.
The Company intends to file a Form 25
(Notification of Removal from Listing) with the SEC on March 10,
2025, and expects the last trading day of the Company’s common
stock on Nasdaq will be March 20, 2025. Following delisting from
Nasdaq, any trading in the Company’s ADSs would occur only in
privately negotiated sales and potentially on an over-the-counter
market if a broker makes a market in the ADSs. There is no
guarantee, however, that a broker will make such a market or that
trading of the ADSs will continue on an over-the-counter market or
otherwise.
The Company also intends to file a Form 15
(Certification and Notice of Termination From Registration) with
the SEC on or about March 20, 2025. Upon filing, the Company’s
obligation to file periodic reports with the SEC, including Forms
20-F and 6-K, will be suspended immediately and will terminate when
deregistration becomes effective 90 days after the Form 15 is
filed.
Forward Looking Statements
This press release contains express or implied
forward-looking statements that are based on the Company
management's belief and assumptions and on information currently
available to the Company’s management. Forward-looking statements
in this press release include, but are not limited to, statements
regarding the Company’s intention to delist from Nasdaq and to
deregister from the SEC. Although the Company believes that the
expectations reflected in these forward-looking statements are
reasonable, these statements relate to future events and involve
known and unknown risks, uncertainties and other factors that may
cause the Company’s actual actions to be materially different from
any future actions expressed or implied by these forward-looking
statements. The forward-looking statements in this press release
represent the Company’s views as of the date of this press release.
While the Company may elect to update these forward-looking
statements at some point in the future, the Company has no current
intention of doing so except to the extent required by applicable
law. You should therefore not rely on these forward-looking
statements as representing the Company’s views as of any date
subsequent to the date of this press release.
For further information, please contact:
Meru AdvisorsLee M.
Sternlstern@meruadvisors.com
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Feb 2025 to Mar 2025
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Mar 2024 to Mar 2025